Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Non-rapidly Progressive CRPC
NCT00976755Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Sep 2009
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in castration-resistant prostate cancer (CRPC), sponsored by Swiss Group for Clinical Cancer Research. Started Sep 2009; status: completed.
02
Drugs
everolimus
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT00976755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00976755.